Disorders of vision in multiple sclerosis

References

• Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389:1336–1346.
   PubMed Web of Science ®Google Scholar
• Tao C, Simpson S Jr. van der Mei I et al. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:1343–1349.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–2197.
   PubMed Web of Science ®Google Scholar
• Tintore M, À Rovira, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138:1863–1874.
   PubMed Web of Science ®Google Scholar
• Barzegar M, Shaygannejad V, Mirmosayyeb O, et al. Progression to Secondary Progressive Multiple Sclerosis and its Early Risk Factors: a Population-based Study (2171). Neurology. 2020;94:2171.
   Web of Science ®Google Scholar
• Fambiatos A, Jokubaitis V, Horakova D, et al. Risk of secondary progressive multiple sclerosis: a longitudinal study. Mult Scler. 2020;26:79–90.
   Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90: 777–788.
   Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376:209–220.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–1273.
   PubMed Web of Science ®Google Scholar
• van der Mei I, Lucas RM, Taylor BV, et al. Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Mult Scler. 2016;22:461–469.
   Web of Science ®Google Scholar
• Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20:739–746.
   PubMed Web of Science ®Google Scholar
• Irizar H, Muñoz-Culla M, Zuriarrain O, et al. HLA-DRB1*15:01 and multiple sclerosis: a female association? Mult Scler. 2012;18:569–577.
   PubMed Web of Science ®Google Scholar
• Cree BA. Multiple sclerosis genetics. Handb Clin Neurol. 2014;122:193–209.
   Google Scholar
• Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: a Comprehensive Review. Neurol Ther. 2018;7:59–85.
   PubMed Web of Science ®Google Scholar
• Abrahamyan S, Eberspächer B, Hoshi MM, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:681–686.
   PubMed Web of Science ®Google Scholar
• Hughes J, Jokubaitis V, Lugaresi A, et al. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurol. 2018;75:1407–1415.
   Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135:2925–2937.
   PubMed Web of Science ®Google Scholar
• von Essen MR, Ammitzbøll C, Hansen RH, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142:120–132.
   PubMed Web of Science ®Google Scholar
• Kunkl M, Frascolla S, Amormino C, et al. T Helper Cells: the Modulators of Inflammation in Multiple Sclerosis. Cells. 2020 Feb 19;9(2):482.
   Google Scholar
• Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol. 2013;260:1272–1285.
   Web of Science ®Google Scholar
• Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7:185–217.
   PubMed Web of Science ®Google Scholar
• Hickman S, Izzy S, Sen P, et al. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359–1369.
   PubMed Web of Science ®Google Scholar
• Mancini A, Tantucci M, Mazzocchetti P, et al. Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiol Dis. 2018;113:97–108.
   Web of Science ®Google Scholar
• Thompson KK, Tsirka SE. The Diverse Roles of Microglia in the Neurodegenerative Aspects of Central Nervous System (CNS) Autoimmunity. Int J Mol Sci. 2017;18(3):504.
   Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011;259:659–681.
   PubMed Web of Science ®Google Scholar
• Gaitán MI, Shea CD, Evangelou IE, et al. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol. 2011;70:22–29.
   Web of Science ®Google Scholar
• Platten M, Lanz T, Bendszus M, et al. [Clinically isolated syndrome]. Nervenarzt. 2013;84:1247–1259.
   Web of Science ®Google Scholar
• Clinically Isolated Efendi H. Syndromes: clinical Characteristics, Differential Diagnosis, and Management. Noro Psikiyatr Ars. 2015;52:S1–s11.
   Google Scholar
• Oreja-Guevara C, Noval S, Alvarez-Linera J, et al. Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study. PLoS One. 2012;7:e33907.
   PubMed Web of Science ®Google Scholar
• Pérez-Rico C, Ayuso-Peralta L, Rubio-Pérez L, et al. Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients. Invest Ophthalmol Vis Sci. 2014;55:6127–6131.
   PubMed Web of Science ®Google Scholar
• Zimmermann HG, Knier B, Oberwahrenbrock T, et al. Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurol. 2018;75:1071–1079.
   PubMed Web of Science ®Google Scholar
• Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354:1273–1280.
   PubMed Web of Science ®Google Scholar
• Kale N. Optic neuritis as an early sign of multiple sclerosis. Eye Brain. 2016;8:195–202.
   PubMed Web of Science ®Google Scholar
• Hoch MJ, Bruno MT, Shepherd TM. Advanced MRI of the Optic Nerve. J Neuroophthalmol. 2017;37:187–196.
   Web of Science ®Google Scholar
• Britze J, Frederiksen JL. Optical coherence tomography in multiple sclerosis. Eye (Lond). 2018;32:884–888.
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Mandel G, Anderson S, et al. Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci. 2011;308:117–123.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Kezuka T, Shikishima K, et al. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. Ophthalmology. 2019;126:1385–1398.
   Web of Science ®Google Scholar
• Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One. 2013;8:e66151.
   PubMed Web of Science ®Google Scholar
• Iorga RE, Moraru A, Ozturk MR, et al. The role of Optical Coherence Tomography in optic neuropathies. Rom J Ophthalmol. 2018;62:3–14.
   Google Scholar
• Bsteh G, Hegen H, Teuchner B, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler. 2019;25:196–203.
   Web of Science ®Google Scholar
• Jankowska-Lech I, Wasyluk J, Palasik W, et al. Peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography in different clinical subtypes of multiple sclerosis. Mult Scler Relat Disord. 2019;27:260–268.
   Web of Science ®Google Scholar
• Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15:574–584.
   PubMed Web of Science ®Google Scholar
• Carcelén-Gadea M, Quintanilla-Bordás C, Gracia-García A, et al. Functional and structural changes in the visual pathway in multiple sclerosis. Brain Behav. 2019;9:e01467.
   Web of Science ®Google Scholar
• Lambe J, Fitzgerald KC, Murphy OC, et al. Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis. Neurology 2021 Apr 20;96(16):e2058–e2069.
   Google Scholar
• Spain RI, Liu L, Zhang X et al. Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis. Br J Ophthalmol. 2018;102:520–524.
   Web of Science ®Google Scholar
• Lanzillo R, Cennamo G, Criscuolo C, et al. Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. Mult Scler. 2018;24:1706–1714.
   PubMed Web of Science ®Google Scholar
• Higashiyama T, Nishida Y, Ohji M. Optical coherence tomography angiography in eyes with good visual acuity recovery after treatment for optic neuritis. PLoS One. 2017;12:e0172168.
   PubMed Web of Science ®Google Scholar
• Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler. 2017;23:1309–1319.
   Web of Science ®Google Scholar
• Behbehani R, Abu Al-Hassan A, Al-Salahat A, et al. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One. 2017;12:e0172120.
   Web of Science ®Google Scholar
• Pihl-Jensen G, Schmidt MF, Frederiksen JL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: a review. Clin Neurophysiol. 2017;128:1234–1245.
   Web of Science ®Google Scholar
• Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol. 2009;118:129–137.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–588.
   PubMed Web of Science ®Google Scholar
• Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944–949.
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727–732.
   PubMed Web of Science ®Google Scholar
• The Optic Neuritis Study G. Multiple Sclerosis Risk After Optic Neuritis: final Optic Neuritis Treatment Trial Follow-up. Arch Neurol. 2008;65:727–732.
   Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815.
   PubMed Web of Science ®Google Scholar
• Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–481.
   PubMed Web of Science ®Google Scholar
• Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88:632–638.
   PubMed Web of Science ®Google Scholar
• Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology. 2011;18:69–79.
   Google Scholar
• Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006;28:348–353.
   PubMed Web of Science ®Google Scholar
• Nicchia GP, Mastrototaro M, Rossi A, et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia. 2009;57:1363–1373.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Tobin WO, Majed M, et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018;136:419–422.
   Web of Science ®Google Scholar
• Matthews L, Enzinger C, Fazekas F, et al. MRI in Leber’s hereditary optic neuropathy: the relationship to multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:537–542.
   PubMed Web of Science ®Google Scholar
• Bianco A, Bisceglia L, Trerotoli P, et al. Leber’s hereditary optic neuropathy (LHON) in an Apulian cohort of subjects. Acta Myol. 2017;36:163–177.
   Google Scholar
• Zuccarelli M, Vella-Szijj J, Serracino-Inglott A, et al. Treatment of Leber’s hereditary optic neuropathy: an overview of recent developments. Eur J Ophthalmol. 2020;30:1220–1227.
   Web of Science ®Google Scholar
• Kampylafka EI, Alexopoulos H, Kosmidis ML, et al. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013;8:e55843.
   PubMed Web of Science ®Google Scholar
• Shekhar S, Sonani H, Desai J, et al. Systemic Lupus Erythematosus Presenting With Severe Optic Disc Edema. Pediatr Neurol. 2018;84:53–54.
   Web of Science ®Google Scholar
• Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69:780–781.
   PubMed Web of Science ®Google Scholar
• Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. Qjm. 2009;102:449–460.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15:302.
   Web of Science ®Google Scholar
• Lazarewicz K, Watson P. Giant cell arteritis. Bmj. 2019;365:l1964.
   Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461.
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Mackie S, Harden C, et al. Temporal artery biopsy: audit of histological diagnosis. Rheumatology (Oxford). 2020;59:678–679.
   Web of Science ®Google Scholar
• Sharma S, Ang M, Najjar RP, et al. Optical coherence tomography angiography in acute non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2017;101:1045–1051.
   Web of Science ®Google Scholar
• Jouve L, Benrabah R, Héron E, et al. Multiple Sclerosis-related Uveitis: does MS Treatment Affect Uveitis Course? Ocul Immunol Inflamm. 2017;25:302–307.
   PubMed Web of Science ®Google Scholar
• Messenger W, Hildebrandt L, Mackensen F, et al. Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol. 2015;99:205–209.
   PubMed Web of Science ®Google Scholar
• Petropoulos IN, Kamran S, Li Y, et al. Corneal Confocal Microscopy: an Imaging Endpoint for Axonal Degeneration in Multiple Sclerosis. Invest Ophthalmol Vis Sci. 2017;58:3677–3681.
   PubMed Web of Science ®Google Scholar
• Leigh RJ, Zee DS. The Neurology of Eye Movements. Oxford, UK: Oxford University Press; 2015.
   Google Scholar
• Lekwuwa GU, Barnes GR. Cerebral control of eye movements. I. The relationship between cerebral lesion sites and smooth pursuit deficits. Brain. 1996;119(Pt 2)):473–490.
   Web of Science ®Google Scholar
• King WM. Binocular coordination of eye movements–Hering’s Law of equal innervation or uniocular control? Eur J Neurosci. 2011;33:2139–2146.
   Web of Science ®Google Scholar
• Frohman EM, Fujimoto JG, Frohman TC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008;4:664–675.
   PubMedGoogle Scholar
• Zee DS, Hain TC, Carl JR. Abduction nystagmus in internuclear ophthalmoplegia. Ann Neurol. 1987;21:383–388.
   PubMed Web of Science ®Google Scholar
• Nij Bijvank JA, van Rijn LJ, Kamminga M, et al. Saccadic fatigability in the oculomotor system. J Neurol Sci. 2019;402:167–174.
   Web of Science ®Google Scholar
• Hejtmancik JF. Ophthalmology: cataracts dissolved. Nature. 2015;523:540–541.
   Web of Science ®Google Scholar
• Zhou M, Bakri SJ, Pershing S. Risk factors for incident central serous retinopathy: case-control analysis of a US national managed care population. Br J Ophthalmol. 2019;103:1784–1788.
   Web of Science ®Google Scholar
• Heath G, Airody A, Gale RP. The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis. Drugs. 2017;77:303–311.
   Web of Science ®Google Scholar
• Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. 2021;96:e783–e797.
   PubMed Web of Science ®Google Scholar
• Savant V, Gillow T. Interferon-associated retinopathy. Eye (Lond). 2003;17:534–536.
   Web of Science ®Google Scholar
• Feroze KB, Wang J. Interferon Induced Retinopathy. In: tatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
   Google Scholar
• Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339–347.
   PubMed Web of Science ®Google Scholar
• Schelenz D, Kleiter I, Schöllhammer J, et al. [Early onset of fingolimod-associated macular edema]. Ophthalmologe. 2018;115:424–428.
   Web of Science ®Google Scholar
• Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117–1126.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cohen JA, Coles AJ, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87:1985–1992.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012;78:436–437.
   PubMed Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742–750.
   PubMed Web of Science ®Google Scholar
• Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis. 1997;176:250–254.
   PubMed Web of Science ®Google Scholar
• Ryschkewitsch CF, Jensen PN, Monaco MC et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010;68:384–391.
   Web of Science ®Google Scholar
• Mancinelli CR, Scarpazza C, Cordioli C, et al. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Mult Scler. 2021;27:790–794.
   Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–446.
   PubMed Web of Science ®Google Scholar